Timothy Aaron Graubert

This study identifies SRSF2 and U2AF1 mutations as biomarkers of sensitivity to ATR-CHK1 pathway inhibitors and RUNX1 mutations as a mechanism of resistance in MDS/AML.

The paper shows that oncogene-imposed dosage constraints can lead to mutations resembling tumor suppressor loss, which are essential in APL.

The paper identifies CD43 as a glyco-immune checkpoint that inhibits human macrophage phagocytosis, showing that O-linked glycosylation and sialylation pathways regulate this process in AML.